Skip to content

Levosimendan joint participation with injection efficacy and safety for the treatment of acute heart failure with low blood pressure

Levosimendan joint participation with injection efficacy and safety for the treatment of acute heart failure with low blood pressure

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2100004332
Enrollment
Unknown
Registered
2020-10-25
Start date
2020-11-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute heart failure

Interventions

Sponsors

Shanghai Tongren Hospital Ethics Committee
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: (1) Western medicine diagnosis to satisfy the diagnosis and treatment of heart failure in 2018 China's guide to the relevant standards, the BNP > 400 pg/ml, LVEF 40% or less, according to the traditional Chinese medicine new medicine clinical research guiding principles of TCM, syndrome differentiation for a better mousetrap Yang deficiency syndrome, according to the New York heart association (NYHA) cardiac function classification standard class is III ~ IV; (2) no allergy to Chinese native medicine preparation; (3) the patients' informed consent.

Exclusion criteria

Exclusion criteria: (1) Severe liver and kidney function is not complete, severe infection, malignancy, systemic autoimmune disease; (2) The other heart diseases such as congenital heart disease, acute myocardial infarction or serious heart valve disease, etc.; (3) don't cooperate with treatment, quit or deaths.

Design outcomes

Primary

MeasureTime frame
CI;R;SVI;BP;CO;SVRI;SO2;HR;

Countries

China

Contacts

Public ContactFang Yuan

Tongren Hospital of Shanghai

yuanfangsh@126.com+86 18121226761

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026